Outcomes of a Prospective Trial of Intravenous Milrinone For Exacerbations of Congestive Heart Failure OPTIME-CHF JAMA 2002
Not indicated in routine use with standard medica therapy.
No difference in primary end point between Milrinone and placebo.
Higher instance of atrial arrhythmia and hypotension with Milrinone.
Milrinone is associated a 30% increase in mortality
Repeat hospitalization for cardiovascular causes within 60 days of discharge.
Broad Population with systolic dysfunction
Without low output syndrome
Randomized, Control, Double Blinded
Milrinone versus Placebo